

Global T-Cell Lymphoma Market & Clinical Pipeline Insight

<https://marketpublishers.com/r/GA1F1044ECCEN.html>

Date: March 2016

Pages: 168

Price: US\$ 1,800.00 (Single User License)

ID: GA1F1044ECCEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Immune system consists of various cells that impart resistance to body against foreign entities. They also prevent the development of aberrant cells in the body to maintain its normal functioning. However, it has been noted that these cells are also liable for deterioration leading to diseases development. For instance, T-cell lymphoma is cancer causing unrestricted growth of T-cells leading to impaired immune system. Investigators have identified different T-cell malignancies that cause high morbidity and mortality. As a result, several cancer therapeutics have been developed in past years to prevent T-cell lymphoma proliferation and progression.

T-cell lymphoma is divided into several disease segments based on their pathophysiology that causes difficulty in identification and treatment. Most of the therapeutics have been developed for the Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL) which affects blood and skin, respectively. Other subcategories of T-cell lymphoma are largely untouched due to which large unmet necessities could be observed. For instance, Adult T-cell lymphoma is found in 2%-5% patients suffering from Human T-Lymphotropic Viruses, type I (HTLV-1) infection. Generally chemotherapeutics approaches are used which have modest safety and efficacy profiles. As a result, appropriate therapeutics is not available leading to high unmet medical necessities giving emphasis on development of innovative modalities for T-cell lymphoma treatment.

With time, new modalities are expected to be developed as underlying principles behind T-cell lymphoma would be deciphered. For instance, investigators developed extracorporeal photopheresis as an advanced method that could improve survival in

patients. Low toxicity and activation of treatment on demand are among one of the most sought features. This procedure could also be used with other therapeutics to achieve better pharmacological effects. Despite these benefits, its utility is limited because of special procedure requiring patients to stay in hospital for T-cell lymphoma treatment. This scenario indicates that more research and development is required for new and improved T-cell lymphoma therapeutics. Some of the progress has been made by developing immunotoxin, HDAC inhibitors, monoclonal antibodies and other investigational therapeutics.

Technological advancements are expected to help the investigators to develop better therapeutics and increase the discovery rates. Increased investments in research and development are expected to help in development of better therapeutic with superior pharmacological and commercialization potential. They are expected to offer severe competition to existing therapeutics due to which more revenues are expected to be generated. Lots of opportunity are available as myriad of candidates with different biological properties are under T-cell lymphoma clinical trials. Cancer market is expected to witness introduction of several innovative products which will help the pharmaceutical companies to generate significant revenues. These products are at different stages of clinical trials due to which they would take some time before entering in global market. In this way, future T-cell lymphoma therapeutics looks optimistic due to their superior pharmacological profiles.

“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight:

Mechanism of T-Cell Lymphoma Therapeutics

T-Cell Lymphoma Drug Market Overview

T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase

T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma

T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs

Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs

Marketed T-Cell Lymphoma Drug Clinical Insight

Marketed T-Cell Lymphoma Drugs: 15 Drugs

T-Cell Lymphoma Drug Market Future Prospects

Contents

1. T-CELL LYMPHOMA MARKET ANALYSIS

2. MECHANISM OF T-CELL LYMPHOMA THERAPEUTICS

3. T-CELL LYMPHOMA DRUG MARKET OVERVIEW

3.1 Current Market Scenario

3.2 T Cell Lymphoma Clinical Pipeline Overview

4. T-CELL LYMPHOMA DRUG MARKET DYNAMICS

4.1 Favorable Market Parameters

4.2 Commercialization Challenges

5. T-CELL LYMPHOMA DRUG MARKET FUTURE PROSPECTS

6. T CELL LYMPHOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

6.1 Research

6.2 Preclinical

6.3 Clinical

6.4 Phase-I

6.5 Phase-I/II

6.6 Phase-II

6.7 Phase-II/III

6.8 Phase-III

7. MARKETED T CELL LYMPHOMA DRUG CLINICAL INSIGHT

7.1 Belinostat (Beleodaq)

7.2 Denileukin Diftitox (ONTAK)

7.3 Mogamulizumab (Poteligeo)

7.4 Brentuximab Vedotin (Adcetris)

7.5 Pralatrexate (Difolta/Folotyn)

7.6 Interferon gamma 1a Biosimilar (Imunomax-?)

7.7 Nelarabine (Arranon/ Atriance)

7.8 Vorinostat (Zolinza)

- 7.9 Romidepsin (Istodax)
- 7.10 Bexarotene Topical (Targretin Gel)
- 7.11 Bexarotene Oral (Targretin Oral)
- 7.12 Chlormethine (Ledaga/Valchlor)
- 7.13 Methoxsalen Solution (UVADEX)
- 7.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
- 7.15 Interferon alpha-2a (Roferon-A)

8. DISCONTINUED & NO DEVELOPMENT REPORTED IN T-CELL LYMPHOMA DRUG IN CLINICAL PIPELINE

- 8.1 Discontinued
- 8.2 No Development Reported

9. COMPETITIVE LANDSCAPE

- 9.1 Actelion Pharmaceuticals
- 9.2 Allos Therapeutics
- 9.3 Astellas Pharma
- 9.4 BioCryst Pharmaceuticals
- 9.5 Bristol-Myers Squibb
- 9.6 Chipscreen Biosciences
- 9.7 Celgene Corporation
- 9.8 Eisai
- 9.9 Genmab
- 9.10 Galderma
- 9.11 Inovio Pharmaceuticals
- 9.12 Johnson & Johnson Pharmaceutical Research & Development
- 9.13 Karyopharm Therapeutics
- 9.14 Kyowa Hakko Kirin
- 9.15 Nippon Kayaku
- 9.16 Novartis
- 9.17 Neumedicines
- 9.18 Onyx Pharmaceuticals
- 9.19 Roche
- 9.20 Seattle Genetics
- 9.21 Shionogi
- 9.22 Soligenix
- 9.23 TetraLogic Pharmaceuticals

9.24 ZIOPHARM Oncology

List Of Figures

LIST OF FIGURES

- Figure 1-1: Main Types of Blood Cancer
- Figure 1-2: Types of White Blood Cells (WBC)
- Figure 1-3: Types of Lymphoma
- Figure 1-4: Major Type of T-Cell Lymphoma
- Figure 1-5: Type of Anaplastic Large Cell Lymphoma
- Figure 1-6: Type of Uncommon T-Cell Lymphomas
- Figure 2-1: Extracorporeal Photopheresis (ECP)
- Figure 2-2: Mechanism of Bexarotene
- Figure 2-3: Mechanism of Pralatrexate
- Figure 2-4: Mechanism of Vorinostat
- Figure 2-5: Mechanism of Denileukin Diftitox
- Figure 2-6: Mechanism of Romidepsin
- Figure 2-7: Mechanism of Alemtuzumab
- Figure 3-1: T-Cell Lymphoma Pipeline by Phase(%), 2016
- Figure 3-2: T-Cell Lymphoma Pipeline by Phase(Numbers), 2016
- Figure 3-3: T-Cell Lymphoma Pipeline by Phase (%), 2016
- Figure 3-4: T-Cell Lymphoma Pipeline by Phase (Numbers), 2016
- Figure 4-1: T-Cell Lymphoma Drug Market Favorable Parameters
- Figure 4-1: T-Cell Lymphoma Drug Market Commercialization Challenges

List Of Tables

LIST OF TABLES

Table 1-1: Staging of T-Cell Lymphoma

I would like to order

Product name: Global T-Cell Lymphoma Market & Clinical Pipeline Insight

Product link: <https://marketpublishers.com/r/GA1F1044ECCEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA1F1044ECCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970